Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma

Table 1 Clinicopathological characteristics of patients with stage II/III gastric cancer n (%)

Characteristic	Surgery alone	Surgery + chemotherapy	P value
No. of patients	117	169
Age (yr)
Median (range)	62 (31-80)	58 (25-80)	0.063
< 70	89 (76.1)	142 (84.0)	0.093
≥ 70	28 (23.9)	27 (16.0)
Sex, n			0.924
Men	83 (70.9)	119 (70.4)
Women	34 (29.1)	50 (20.6)
Karnofsky performance status			0.515
≥ 90	116 (99.1)	166 ( 98.2)
≥ 80	1(0.9)	3 (1.8)
Tumor location			0.054
Proximal	77 (65.8)	92 (54.4)
Distal	40 (34.2)	77 (45.6)
Histological grade			0.120
High differentiation	0 (0.0)	4 (2.4)
Moderate differentiation	32 (27.4)	35 (20.7)
Low differentiation	85 (72.6)	130 (76.9)
Gloss type			0.429
Protrusion	41 (35.0)	64 (37.9)
Ulcer	71 (60.7)	102 (60.4)
Infiltration	5 (4.3)	3 (1.8)
Tumor size			0.359
< 5 cm	41 (35.3)	51 (30.2)
≥ 5 cm	75 (64.7)	118 (60.8)
Preoperative serum CEA			0.207
Median (range)	2.42 (0.2–326.8)	2.235 (0.2–265.5)
Preoperative serum CA19-9			0.729
Median (range)	11.33 (0.6–206.9)	10.83 (0.6–3098.0)
CEA tumor status			0.792
–	12 (10.3)	19 (11.2)
+	105 (89.7)	150 (88.8)
P53 tumor status			0.813
–	27 (23.1)	37 (21.9)
+	90 (76.9)	132 (78.1)
T category			0.182
T1	0 (0.0)	2 (1.2)
T2	7 (6.0)	20 (11.8)
T3	91 (77.8)	116 (68.6)
T4	19 (12.6)	31 (18.3)
N category			0.069
N0	31 (26.5)	37 (21.9)
N1	19 (16.2)	29 (17.2)
N2	33 (28.2)	31 (18.3)
N3	34 (29.1)	72 (42.6)
AJCC stage (7th)			0.066
IIA	29 (24.8)	38 (22.5)
IIB	11 (9.4)	26 (15.4)
IIIA	34 (29.1)	34 (20.1)
IIIB	40 (34.2)	56 (33.1)
IIIC	3 (2.6)	15 (8.9)

CEA: Carcinoembryonic antigen.